Virology

分子生物学核心已经运作了12年，并提供了国家的- 用于许多分子生物学技术和重组蛋白表达的现有技术方法， 洁净.分子生物学核心的主要目标仍然是： 1.收集和维持合适的质粒载体和宿主，用于表达HIV/SIV和相关的 重组蛋白 2.为HIV/SIV重组质粒的构建和高效表达提供服务 和相关蛋白质，包括用于免疫分析的HLA四聚体。 3.为HIV/SIV及其相关蛋白的纯化提供服务。 4.建立携带HIV/SIV基因的质粒和重组HIV/SIV的现场储存库 proteins. 5.为构建感染性HIVISIV前病毒克隆提供服务， 感兴趣的基因突变。 6.培训人员协助质粒构建和表达/纯化的各个阶段 为促进技术转让， 分子生物学核心在过去一年中平均每年帮助25名以上的CFAR成员。 融资期。在上一个供资期间，核心项目平均每年的退款超过40，000美元 （共计180 000美元）。分子生物学核心为UAB CFAR提供了关键试剂和专业知识 资助个人R 01赠款的成员，UAB的国家公司疫苗开发小组 以及一个由多名研究人员资助的项目，以阐明HIV-1逆转录的特征。在 在下一个供资期，核心小组将加大力度，为国际CFAR提供关键试剂 传播和疫苗倡议。因此，对这一机制的支持有助于继续成功地 许多研究人员在艾滋病毒发病机制、疫苗和治疗的不同领域工作， 目前正在UAB进行开发。

The Molecular Biology Core has been in operation for the past twelve years and has provided state-ofthe- art methodologies for numerous molecular biological techniques and recombinant protein expression and purification. The major goals of the Molecular Biology Core remain: 1. To collect and maintain suitable plasmid vectors and host for expression of HIV/SIV and related recombinant proteins 2. To provide a service for construction of recombinant plasmids and high level expression of HIV/SIV and related proteins, including HLA tetramers for immunological analysis. 3. To provide a service for purification of HIV/SIV and related proteins. 4. To establish an onsite repository for plasmids with HIV/SIV genes as well as recombinant HIV/SIV proteins. 5. To provide a service for construction of infectious HIVISIV proviral clones containing defined mutations in genes of interest. 6. To train personnel to assist in the various phases of plasmid construction and expression/purification of recombinant proteins for the purpose of facilitating technology transfer. The Molecular Biology Core has assisted, on average, over 25 CFAR members per year during the last funding period. The Core has averaged over $40,000 per year in chargebacks over the last funding period ($180,000 total). The Molecular Biology Core has provided critical reagents and expertise to UAB CFAR members that have funded individual R01 grants, UAB's National Corporative Vaccine Development Group and a multi-investigator funded program project to elucidate features of the HIV-1 reverse transcription. In the next funding period, the Core will expand its efforts to provide critical reagents for the international CFAR transmission and vaccine initiatives. Support of this facility is thus instrumental for the continued success of numerous investigators working in different areas of HIV pathogenesis, vaccine and therapeutic development currently conducted at UAB.